Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CV Sciences (CVSI) EBIT (2016 - 2025)

Historic EBIT for CV Sciences (CVSI) over the last 14 years, with Q3 2025 value amounting to -$275000.0.

  • CV Sciences' EBIT rose 1935.48% to -$275000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year increase of 5721.33%. This contributed to the annual value of -$2.2 million for FY2024, which is 16517.86% down from last year.
  • Per CV Sciences' latest filing, its EBIT stood at -$275000.0 for Q3 2025, which was up 1935.48% from -$131000.0 recorded in Q2 2025.
  • CV Sciences' 5-year EBIT high stood at $5.8 million for Q1 2023, and its period low was -$8.8 million during Q4 2021.
  • In the last 5 years, CV Sciences' EBIT had a median value of -$889000.0 in 2023 and averaged -$1.3 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 48033.0% in 2023, then plummeted by 11076.02% in 2024.
  • CV Sciences' EBIT (Quarter) stood at -$8.8 million in 2021, then skyrocketed by 75.97% to -$2.1 million in 2022, then skyrocketed by 58.16% to -$889000.0 in 2023, then grew by 27.33% to -$646000.0 in 2024, then soared by 57.43% to -$275000.0 in 2025.
  • Its EBIT was -$275000.0 in Q3 2025, compared to -$131000.0 in Q2 2025 and $11000.0 in Q1 2025.